Armistice Capital LLC Sells 200,000 Shares of Voyager Therapeutics, Inc. $VYGR

Armistice Capital LLC cut its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 4.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,000,000 shares of the company’s stock after selling 200,000 shares during the period. Armistice Capital LLC owned about 7.19% of Voyager Therapeutics worth $15,720,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in VYGR. AQR Capital Management LLC grew its holdings in Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after purchasing an additional 317,927 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Voyager Therapeutics in the 1st quarter valued at about $218,000. Acadian Asset Management LLC raised its holdings in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Voyager Therapeutics by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after purchasing an additional 11,929 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Voyager Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after purchasing an additional 6,748 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 11,511 shares of Voyager Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the transaction, the chief executive officer directly owned 472,549 shares of the company’s stock, valued at $1,828,764.63. The trade was a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. HC Wainwright restated a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. Finally, Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Voyager Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Trading Up 2.5%

NASDAQ:VYGR opened at $3.62 on Thursday. The company’s 50-day moving average price is $3.81 and its 200-day moving average price is $3.93. The company has a market cap of $218.72 million, a P/E ratio of -1.84 and a beta of 1.25. Voyager Therapeutics, Inc. has a twelve month low of $2.83 and a twelve month high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The firm had revenue of $1.19 million for the quarter, compared to the consensus estimate of $8.79 million. On average, analysts expect that Voyager Therapeutics, Inc. will post -1.43 earnings per share for the current year.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.